381 related articles for article (PubMed ID: 26170642)
21. Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients.
Paganini EP; Eschbach JW; Lazarus JM; Van Stone JC; Gimenez LF; Graber SE; Egrie JC; Okamoto DM; Goodkin DA
Am J Kidney Dis; 1995 Aug; 26(2):331-40. PubMed ID: 7645538
[TBL] [Abstract][Full Text] [Related]
22. A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting.
McCloskey C; Ortega MT; Nair S; Garcia MJ; Manevy F
Pharmacoecon Open; 2023 Jan; 7(1):3-36. PubMed ID: 35996066
[TBL] [Abstract][Full Text] [Related]
23. Inflammatory Bowel Disease Patients' Preferences for Subcutaneous versus Intravenous Therapies: A Mixed-Methods Study.
van Deen WK; Khalil C; Bonthala NN; Gale R; Patel DB; Warui E; Melmed GY; Spiegel BMR
Dig Dis; 2023; 41(3):412-421. PubMed ID: 36476714
[TBL] [Abstract][Full Text] [Related]
24. A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis.
Plavina T; Fox EJ; Lucas N; Muralidharan KK; Mikol D
J Clin Pharmacol; 2016 Oct; 56(10):1254-62. PubMed ID: 26835603
[TBL] [Abstract][Full Text] [Related]
25. Considering patient preferences when selecting anti-tumor necrosis factor therapeutic options.
Sylwestrzak G; Liu J; Stephenson JJ; Ruggieri AP; DeVries A
Am Health Drug Benefits; 2014 Apr; 7(2):71-81. PubMed ID: 24991392
[TBL] [Abstract][Full Text] [Related]
26. Patient Preferences for Subcutaneous versus Intravenous Administration of Treatment for Chronic Immune System Disorders: A Systematic Review.
Overton PM; Shalet N; Somers F; Allen JA
Patient Prefer Adherence; 2021; 15():811-834. PubMed ID: 33907384
[TBL] [Abstract][Full Text] [Related]
27. Epinephrine in anaphylaxis: higher risk of cardiovascular complications and overdose after administration of intravenous bolus epinephrine compared with intramuscular epinephrine.
Campbell RL; Bellolio MF; Knutson BD; Bellamkonda VR; Fedko MG; Nestler DM; Hess EP
J Allergy Clin Immunol Pract; 2015; 3(1):76-80. PubMed ID: 25577622
[TBL] [Abstract][Full Text] [Related]
28. Postoperative analgesic effects of intravenous, intramuscular, subcutaneous or oral transmucosal buprenorphine administered to cats undergoing ovariohysterectomy.
Giordano T; Steagall PV; Ferreira TH; Minto BW; de Sá Lorena SE; Brondani J; Luna SP
Vet Anaesth Analg; 2010 Jul; 37(4):357-66. PubMed ID: 20636568
[TBL] [Abstract][Full Text] [Related]
29. Effect of intratesticular injection of xylazine/ketamine combination on canine castration.
Kim JK; Jeong SM; Yi NY; Jeong MB; Lee ES; Nam TC; Seo KM
J Vet Sci; 2004 Jun; 5(2):151-5. PubMed ID: 15192343
[TBL] [Abstract][Full Text] [Related]
30. Rituximab for subcutaneous delivery: Clinical management principles from a nursing perspective.
Carlson J; Cox K; Bedwell K; Ku M
Int J Nurs Pract; 2015 Dec; 21 Suppl 3():1-13. PubMed ID: 26681664
[TBL] [Abstract][Full Text] [Related]
31. Intramuscular versus intravenous anti-D for preventing Rhesus alloimmunization during pregnancy.
Okwundu CI; Afolabi BB
Cochrane Database Syst Rev; 2013 Jan; (1):CD007885. PubMed ID: 23440818
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of recombinant human granulocyte colony-stimulating factor in the rat. Single and multiple dosing studies.
Tanaka H; Kaneko T
Drug Metab Dispos; 1991; 19(1):200-4. PubMed ID: 1708329
[TBL] [Abstract][Full Text] [Related]
33. A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis.
Westhovens R; Houssiau F; Joly J; Everitt DE; Zhu Y; Sisco D; Van Hartingsveldt B; Mascelli MA; Graham MA; Durez P; Bouman-Thio E
J Rheumatol; 2006 May; 33(5):847-53. PubMed ID: 16583466
[TBL] [Abstract][Full Text] [Related]
34. Assessment of ketamine and medetomidine anaesthesia in the domestic rabbit.
Orr HE; Roughan JV; Flecknell PA
Vet Anaesth Analg; 2005 Sep; 32(5):271-9. PubMed ID: 16135208
[TBL] [Abstract][Full Text] [Related]
35. Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic Proteins.
Hamuro L; Kijanka G; Kinderman F; Kropshofer H; Bu DX; Zepeda M; Jawa V
J Pharm Sci; 2017 Oct; 106(10):2946-2954. PubMed ID: 28576695
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics and Acceptability of Subcutaneous Injection of Testosterone Undecanoate.
Turner L; Ly LP; Desai R; Singh GKS; Handelsman TD; Savkovic S; Fennell C; Jayadev V; Conway A; Handelsman DJ
J Endocr Soc; 2019 Aug; 3(8):1531-1540. PubMed ID: 31384715
[TBL] [Abstract][Full Text] [Related]
37. Pediatric procedural sedation with ketamine: time to discharge after intramuscular versus intravenous administration.
Ramaswamy P; Babl FE; Deasy C; Sharwood LN
Acad Emerg Med; 2009 Feb; 16(2):101-7. PubMed ID: 19076105
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of recombinant human luteinizing hormone after intravenous, intramuscular, and subcutaneous administration in monkeys and comparison with intravenous administration of pituitary human luteinizing hormone.
Porchet HC; Le Cotonnec JY; Neuteboom B; Canali S; Zanolo G
J Clin Endocrinol Metab; 1995 Feb; 80(2):667-73. PubMed ID: 7852534
[TBL] [Abstract][Full Text] [Related]
39. Aluminium toxicokinetics after intramuscular, subcutaneous, and intravenous injection of Al citrate solution in rats.
Weisser K; Göen T; Oduro JD; Wangorsch G; Hanschmann KO; Keller-Stanislawski B
Arch Toxicol; 2019 Jan; 93(1):37-47. PubMed ID: 30302509
[TBL] [Abstract][Full Text] [Related]
40. Continuation of subcutaneous or intramuscular injectable contraception when administered by facility-based and community health workers: findings from a prospective cohort study in Burkina Faso and Uganda.
MacLachlan E; Atuyambe LM; Millogo T; Guiella G; Yaro S; Kasasa S; Bukenya J; Nyabigambo A; Mubiru F; Tumusiime J; Onadja Y; Zan LM; Goeum/Sanon C; Kouanda S; Namagembe A
Contraception; 2018 Nov; 98(5):423-429. PubMed ID: 30125558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
